125 related articles for article (PubMed ID: 3543359)
1. 31P nuclear magnetic resonance spectroscopic observation of the intracellular transformations of oncostatic cyclophosphamide metabolites.
Boyd VL; Robbins JD; Egan W; Ludeman SM
J Med Chem; 1986 Jul; 29(7):1206-10. PubMed ID: 3543359
[TBL] [Abstract][Full Text] [Related]
2. Biotransformation of mafosfamide in P388 mice leukemia cells: intracellular 31P-NMR studies.
Sonawat HM; Leibfritz D; Engel J; Hilgard P
Biochim Biophys Acta; 1990 Apr; 1052(1):36-41. PubMed ID: 2322593
[TBL] [Abstract][Full Text] [Related]
3. Conversion of 4-hydroperoxycyclophosphamide and 4-hydroxycyclophosphamide to phosphoramide mustard and acrolein mediated by bifunctional catalysis.
Low JE; Borch RF; Sladek NE
Cancer Res; 1982 Mar; 42(3):830-7. PubMed ID: 7059981
[TBL] [Abstract][Full Text] [Related]
4. NMR spectroscopic studies of intermediary metabolites of cyclophosphamide. A comprehensive kinetic analysis of the interconversion of cis- and trans-4-hydroxycyclophosphamide with aldophosphamide and the concomitant partitioning of aldophosphamide between irreversible fragmentation and reversible conjugation pathways.
Zon G; Ludeman SM; Brandt JA; Boyd VL; Ozkan G; Egan W; Shao KL
J Med Chem; 1984 Apr; 27(4):466-85. PubMed ID: 6708049
[TBL] [Abstract][Full Text] [Related]
5. The interaction of glutathione with 4-hydroxycyclophosphamide and phosphoramide mustard, studied by 31P nuclear magnetic resonance spectroscopy.
Dirven HA; Venekamp JC; van Ommen B; van Bladeren PJ
Chem Biol Interact; 1994 Dec; 93(3):185-96. PubMed ID: 7923439
[TBL] [Abstract][Full Text] [Related]
6. The mechanism of activation of 4-hydroxycyclophosphamide.
Borch RF; Millard JA
J Med Chem; 1987 Feb; 30(2):427-31. PubMed ID: 3806624
[TBL] [Abstract][Full Text] [Related]
7. Half-life of oxazaphosphorines in biological fluids.
Sladek NE; Powers JF; Grage GM
Drug Metab Dispos; 1984; 12(5):553-9. PubMed ID: 6149904
[TBL] [Abstract][Full Text] [Related]
8. O-Methylhydroxylamine as a new trapping reagent for quantitative studies of 4-hydroxycyclophosphamide and aldophosphamide.
Zon G; Ludeman SM; Sweet EM; Egan W; Phillips LR
J Pharm Sci; 1982 Apr; 71(4):443-6. PubMed ID: 7086655
[TBL] [Abstract][Full Text] [Related]
9. Direct detection of the intracellular formation of carboxyphosphamides using nuclear magnetic resonance spectroscopy.
Boal JH; Ludeman SM; Ho CK; Engel J; Niemeyer U
Arzneimittelforschung; 1994 Jan; 44(1):84-93. PubMed ID: 8135883
[TBL] [Abstract][Full Text] [Related]
10. NMR spectroscopic studies of intermediary metabolites of cyclophosphamide. 2. Direct observation, characterization, and reactivity studies of iminocyclophosphamide and related species.
Boyd VL; Summers MF; Ludeman SM; Egan W; Zon G; Regan JB
J Med Chem; 1987 Feb; 30(2):366-74. PubMed ID: 3806617
[TBL] [Abstract][Full Text] [Related]
11. Isolation and mass spectral identification of blood metabolites of cyclophosphamide: evidence for phosphoramide mustard as the biologically active metabolite.
Struck RF; Kirk MC; Witt MH; Laster WR
Biomed Mass Spectrom; 1975 Feb; 2(1):46-52. PubMed ID: 1131393
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacokinetics of cyclophosphamide and cyclophosphamide metabolites in the mouse and their influence on the therapeutic effect of "activated" cyclophosphamide (4-hydroxycyclophosphamide) (author's transl)].
Voelcker G; Haeglsperger R
Arzneimittelforschung; 1982; 32(6):639-47. PubMed ID: 7202370
[TBL] [Abstract][Full Text] [Related]
13. Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation.
Sladek NE; Doeden D; Powers JF; Krivit W
Cancer Treat Rep; 1984 Oct; 68(10):1247-54. PubMed ID: 6395951
[TBL] [Abstract][Full Text] [Related]
14. Effect of stereochemistry on the oxidative metabolism of the cyclophosphamide metabolite aldophosphamide.
Habib AD; Boal JH; Hilton J; Nguyen T; Chang YH; Ludeman SM
Biochem Pharmacol; 1995 Jul; 50(3):429-33. PubMed ID: 7646546
[TBL] [Abstract][Full Text] [Related]
15. In situ preparation and fate of cis-4-hydroxycyclophosphamide and aldophosphamide: 1H and 31P NMR evidence for equilibration of cis- and trans-4-hydroxycyclophosphamide with aldophosphamide and its hydrate in aqueous solution.
Borch RF; Hoye TR; Swanson TA
J Med Chem; 1984 Apr; 27(4):490-4. PubMed ID: 6708051
[TBL] [Abstract][Full Text] [Related]
16. Quantitation of 4-hydroxycyclophosphamide/aldophosphamide in whole blood.
Anderson LW; Ludeman SM; Colvin OM; Grochow LB; Strong JM
J Chromatogr B Biomed Appl; 1995 May; 667(2):247-57. PubMed ID: 7663697
[TBL] [Abstract][Full Text] [Related]
17. Binding of metabolites of cyclophosphamide to DNA in a rat liver microsomal system and in vivo in mice.
Hemminki K
Cancer Res; 1985 Sep; 45(9):4237-43. PubMed ID: 4028012
[TBL] [Abstract][Full Text] [Related]
18. Accelerated decomposition of 4-hydroxycyclophosphamide by human serum albumin.
Kwon CH; Maddison K; LoCastro L; Borch RF
Cancer Res; 1987 Mar; 47(6):1505-8. PubMed ID: 3815352
[TBL] [Abstract][Full Text] [Related]
19. Cyclophosphamide (NSC-26271)-related phosphoramide mustards- recent advances and historical perspective.
Friedman OM; Wodinsky I; Myles A
Cancer Treat Rep; 1976 Apr; 60(4):337-46. PubMed ID: 1277209
[TBL] [Abstract][Full Text] [Related]
20. [Blood level and urinary excretion of activated cyclophosphamide and its deactivation products in man (author's transl)].
Wagner T; Heydrich D; Voelcker G; Hohorst HJ
J Cancer Res Clin Oncol; 1980 Jan; 96(1):79-92. PubMed ID: 7358774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
